---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-038307"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2026-05-27T11:30:35+00:00"
generated_at: "2026-05-27T11:35:58.266367+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences reports PBGENE-HBV eliminates cccDNA in biopsies; pgRNA loss in 100% of patients

## Summary
- Liver biopsy data show 1-log reduction in cccDNA transcripts after two doses at 0.4 mg/kg; indels inactivate remaining <1%.
- pgRNA established as biomarker; 100% of patients (n=6) with detectable pgRNA achieved loss, confirmed by biopsy.
- HBsAg declines in 100% of patients (n=15); first patient maintains durable decline for over 12 months.
- Safety: No DLTs; manageable LNP-related AEs; mitigation protocol resolved Grade 3 hypotension events with no recurrences.
- Next steps: expand enrollment, collect additional biopsies, design Part 2 expansion; update expected by end of 2026.

## SEC filing metadata
- accession: 0001628280-26-038307
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2026-05-27T11:30:35+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828026038307/0001628280-26-038307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828026038307/dtil-20260527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-038307
- JSON: https://secwatch.observer/filing/0001628280-26-038307.json
- Plain text: https://secwatch.observer/filing/0001628280-26-038307.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.